- info@ddregpharma.com
- DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
- USA
- India
- Germany
- Singapore
Patient safety is of utmost importance and the desired outcome for every decision in the drug development process. To protect patients against potential risks associated with a product, robust systems must be established to ensure the precise collection and management of safety-related information. Case processing services and ICSR pharmacovigilance are vital in this effort, offering critical insights into the safety of pharmaceutical products. By gathering adverse drug reactions (ADRs)—both serious and non-serious—from various sources such as healthcare providers, patients, scientific literature, and clinical studies, we can conduct comprehensive cause-and-effect analyses to identify and reduce risks. The safe use of medicines begins with effective ICSR services, where each report plays a significant role in safeguarding public health.
DDReg understands the importance of adhering to global and national ICSR Case Processing requirements. Our ICSR Pharmacovigilance Services comprehensively covers all stages of case reporting, be it case receipt, duplicate check, triage, data entry, quality check, medical review, case publishing and/or final submission to competent authorities.Our highly experienced team processes the ICSRs received from various sources and provides our customers with end-to-end assistance in handling diverse reports.
ICSRs form the cornerstone of post-marketing drug safety surveillance and basis of pharmacovigilance. Different competent authorities around the world have different requirements for ICSRs, especially with respect to their reporting. They contain important information on patients, the adverse events they have experienced, and information regarding the suspected drug. ICSR Pharmacovigilance reports provide a detailed description of the adverse events such as its nature, severity, onset, and outcome which is critical to assess the impact of a drug on patient safety. It also includes information on the concomitant medication and medical history of the patient which helps in identifying if there is a causality between the adverse event and the suspected drug.
It is important for pharmaceutical companies to submit the ICSRs associated with their products to competent authorities within the required timeline. Most authorities have established electronic systems that allow ICSR processing and submission, which streamlines the process and accelerates ICSR submission. This is important to ensure that safety concerns regarding drugs and allied pharmaceutical products are addressed efficiently and promptly. ICSRs that are comprehensive and accurate help support patient safety and competent authorities in making decisions regarding the drug. This contributes towards the overall risk-benefit assessment of drugs that are on the market and aim to safe guard public health.